Search

Your search keyword '"Turletti, A"' showing total 957 results
Start Over Author "Turletti, A"
957 results on '"Turletti, A"'

3. Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial

Author

Poggio, F., Blondeaux, E., Tagliamento, M., Perachino, M., Nardin, S., Conte, B., Giuliano, M., Arpino, G., De Laurentiis, M., Gravina, A., Bisagni, G., Rimanti, A., Turletti, A., Nisticò, C., Magnolfi, E., Gasparro, S., Fabi, A., Garrone, O., Alicicco, M.G., Urracci, Y., Poletti, P., Correale, P., Molinelli, C., Fozza, A., Puglisi, F., Colantuoni, G., Fregatti, P., Boni, L., Lambertini, M., and Del Mastro, L.

Published
2024
Full Text
View/download PDF

6. Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials

Author

Blondeaux, Eva, Xie, Wanling, Carmisciano, Luca, Mura, Silvia, Sanna, Valeria, De Laurentiis, Michelino, Caputo, Roberta, Turletti, Anna, Durando, Antonio, De Placido, Sabino, De Angelis, Carmine, Bisagni, Giancarlo, Gasparini, Elisa, Rimanti, Anita, Puglisi, Fabio, Mansutti, Mauro, Landucci, Elisabetta, Fabi, Alessandra, Arecco, Luca, Perachino, Marta, Bruzzone, Marco, Boni, Luca, Lambertini, Matteo, Del Mastro, Lucia, and Regan, Meredith M.

Published
2024
Full Text
View/download PDF

7. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

Author

Trevisan, B., Pepe, F. F., Vallini, I., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Baldelli, A., Fontana, A., Gambaro, A. R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Sarti, S., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Sarobba, M. G., Schintu, M. G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M. R., Vici, P., Clivio, L., Torri, V., and Cazzaniga, M. E.

Published
2023
Full Text
View/download PDF

11. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

Author

B. Trevisan, F. F. Pepe, I. Vallini, E. Montagna, D. Amoroso, R. Berardi, A. Butera, K. Cagossi, L. Cavanna, M. Ciccarese, S. Cinieri, E. Cretella, E. De Conciliis, A. Febbraro, F. Ferraù, A. Ferzi, A. Baldelli, A. Fontana, A. R. Gambaro, O. Garrone, V. Gebbia, D. Generali, L. Gianni, F. Giovanardi, A. Grassadonia, V. Leonardi, S. Sarti, A. Musolino, M. Nicolini, C. Putzu, F. Riccardi, D. Santini, M. G. Sarobba, M. G. Schintu, G. Scognamiglio, P. Spadaro, C. Taverniti, D. Toniolo, P. Tralongo, A. Turletti, R. Valenza, M. R. Valerio, P. Vici, L. Clivio, V. Torri, M. E. Cazzaniga, and The VICTOR Study Group

Subjects
Medicine, Science
Abstract

Abstract Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT’s activity in a real-life setting of elderly MBC patients. Data of patients ≥ 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75–98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3–4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.

Published
2023
Full Text
View/download PDF

14. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

Author

Lambertini, Matteo, Blondeaux, Eva, Bisagni, Giancarlo, Mura, Silvia, De Placido, Sabino, De Laurentiis, Michelino, Fabi, Alessandra, Rimanti, Anita, Michelotti, Andrea, Mansutti, Mauro, Russo, Antonio, Montemurro, Filippo, Frassoldati, Antonio, Durando, Antonio, Gori, Stefania, Turletti, Anna, Tamberi, Stefano, Urracci, Ylenia, Fregatti, Piero, Razeti, Maria Grazia, Caputo, Roberta, De Angelis, Carmine, Sanna, Valeria, Gasparini, Elisa, Agostinetto, Elisa, de Azambuja, Evandro, Poggio, Francesca, Boni, Luca, and Del Mastro, Lucia

Published
2023
Full Text
View/download PDF

25. Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Author

Fabio Puglisi, Lorenzo Gerratana, Matteo Lambertini, Marcello Ceppi, Luca Boni, Filippo Montemurro, Stefania Russo, Claudia Bighin, Michelino De Laurentiis, Mario Giuliano, Giancarlo Bisagni, Antonio Durando, Anna Turletti, Ornella Garrone, Andrea Ardizzoni, Teresa Gamucci, Giuseppe Colantuoni, Adriano Gravina, Sabino De Placido, Francesco Cognetti, and Lucia Del Mastro

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the absolute treatment effect through a composite measure of recurrence risk (CPRS) in patients with hormone receptor-positive HER2-negative eBC. CPRS was estimated through Cox proportional hazards models applied to the different clinicopathological features. The treatment effect was compared to the values of CPRS by using the Sub-population Treatment Effect Pattern Plot (STEPP) process. The Disease-Free Survival (DFS)-oriented STEPP analysis showed distinct patterns of relative treatment effect with respect to CPRS. Overall, 5-year DFS differed across CPRS quartiles ranging from 95.2 to 66.4%. Each CPRS quartile was characterized by a different patients’ composition, especially for age, lymph node involvement, tumor size, estrogen and progesterone receptor expression, and Ki-67. A number needed to treat of 154 and 6 was associated with the lowest and the highest CPRS quartile, respectively. Dose-dense adjuvant chemotherapy showed a consistent benefit in node-positive eBC patients with hormone receptor-positive HER2-negative disease, but its effect varied according to CPRS.

Published
2021
Full Text
View/download PDF

34. Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Author

Puglisi, Fabio, Gerratana, Lorenzo, Lambertini, Matteo, Ceppi, Marcello, Boni, Luca, Montemurro, Filippo, Russo, Stefania, Bighin, Claudia, De Laurentiis, Michelino, Giuliano, Mario, Bisagni, Giancarlo, Durando, Antonio, Turletti, Anna, Garrone, Ornella, Ardizzoni, Andrea, Gamucci, Teresa, Colantuoni, Giuseppe, Gravina, Adriano, De Placido, Sabino, Cognetti, Francesco, and Del Mastro, Lucia

Published
2021
Full Text
View/download PDF

35. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Author

Cicchiello, F., Riva, F., Vallini, I., Mazza, M., Bonfadini, C., Bordin, E., Canicattì, M., Cappuccio, F., Collovà, E., De Angelis, C., Desorte, R., Donati, S., Drudi, G., Galanti, D., Mocerino, C., Orlando, L., Pellegrino, B., Pizzuti, L., Ridolfi, C., Rocca, A., Sarti, D., Spagnoletti, I., Tinari, N., Vandone, A., Vizzini, L., Cazzaniga, M.E., Pinotti, G., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Fiorentini, G., Fontana, A., Gambaro, A.R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Marchetti, P., Melegari, E., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Saracchini, S., Sarobba, M.G., Schintu, M.G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M.R., Vici, P., Clivio, L., and Torri, V.

Published
2019
Full Text
View/download PDF

37. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

Author

Trevisan, B, Pepe, F, Vallini, I, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Baldelli, A, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Sarti, S, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Clivio, L, Torri, V, Cazzaniga, M, Trevisan B., Pepe F. F., Vallini I., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Baldelli A., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Sarti S., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Clivio L., Torri V., Cazzaniga M. E., Trevisan, B, Pepe, F, Vallini, I, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Baldelli, A, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Sarti, S, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Clivio, L, Torri, V, Cazzaniga, M, Trevisan B., Pepe F. F., Vallini I., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Baldelli A., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Sarti S., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Clivio L., Torri V., and Cazzaniga M. E.

Abstract

Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT’s activity in a real-life setting of elderly MBC patients. Data of patients ≥ 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75–98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3–4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.

Published
2023

38. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

Author

Cazzaniga, Marina Elena, primary, Pronzato, Paolo, additional, Amoroso, Domenico, additional, Bernardo, Antonio, additional, Biganzoli, Laura, additional, Bisagni, Giancarlo, additional, Blasi, Livio, additional, Bria, Emilio, additional, Cognetti, Francesco, additional, Crinò, Lucio, additional, De Laurentiis, Michelino, additional, Del Mastro, Lucia, additional, De Placido, Sabino, additional, Beano, Alessandra, additional, Ferraù, Francesco, additional, Foladore, Silva, additional, Forcignanò, Rosachiara, additional, Gamucci, Teresa, additional, Garrone, Ornella, additional, Gennari, Alessandra, additional, Giordano, Monica, additional, Giotta, Francesco, additional, Giovanardi, Filippo, additional, Latini, Luciano, additional, Livi, Lorenzo, additional, Marchetti, Paolo, additional, Mattioli, Rodolfo, additional, Michelotti, Andrea, additional, Montemurro, Filippo, additional, Putzu, Carlo, additional, Riccardi, Ferdinando, additional, Ricciardi, Giuseppina, additional, Romagnoli, Emanuela, additional, Sarobba, Giuseppina, additional, Spazzapan, Simon, additional, Tagliaferri, Pierosandro, additional, Tinari, Nicola, additional, Tonini, Giuseppe, additional, Turletti, Anna, additional, Verusio, Claudio, additional, Zambelli, Alberto, additional, and Mustacchi, Giorgio, additional

Published
2023
Full Text
View/download PDF

39. Supplementary Table S12 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials

Author

Conte, Benedetta, primary, Boni, Luca, primary, Bisagni, Giancarlo, primary, Durando, Antonio, primary, Sanna, Giovanni, primary, Gori, Stefania, primary, Garrone, Ornella, primary, Tamberi, Stefano, primary, De Placido, Sabino, primary, Schettini, Francesco, primary, Pazzola, Antonio, primary, Ponzone, Riccardo, primary, Montemurro, Filippo, primary, Lunardi, Gianluigi, primary, Notaro, Rosario, primary, De Angioletti, Maria, primary, Turletti, Anna, primary, Mansutti, Mauro, primary, Puglisi, Fabio, primary, Frassoldati, Antonio, primary, Porpiglia, Mauro, primary, Fabi, Alessandra, primary, Generali, Daniele, primary, Scognamiglio, Giovanni, primary, Rossi, Maura, primary, Brasó-Maristany, Fara, primary, Prat, Aleix, primary, Cardinali, Barbara, primary, Piccioli, Patrizia, primary, Serra, Martina, primary, Lastraioli, Sonia, primary, Bighin, Claudia, primary, Poggio, Francesca, primary, Lambertini, Matteo, primary, and Del Mastro, Lucia, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure S1 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials

Author

Conte, Benedetta, primary, Boni, Luca, primary, Bisagni, Giancarlo, primary, Durando, Antonio, primary, Sanna, Giovanni, primary, Gori, Stefania, primary, Garrone, Ornella, primary, Tamberi, Stefano, primary, De Placido, Sabino, primary, Schettini, Francesco, primary, Pazzola, Antonio, primary, Ponzone, Riccardo, primary, Montemurro, Filippo, primary, Lunardi, Gianluigi, primary, Notaro, Rosario, primary, De Angioletti, Maria, primary, Turletti, Anna, primary, Mansutti, Mauro, primary, Puglisi, Fabio, primary, Frassoldati, Antonio, primary, Porpiglia, Mauro, primary, Fabi, Alessandra, primary, Generali, Daniele, primary, Scognamiglio, Giovanni, primary, Rossi, Maura, primary, Brasó-Maristany, Fara, primary, Prat, Aleix, primary, Cardinali, Barbara, primary, Piccioli, Patrizia, primary, Serra, Martina, primary, Lastraioli, Sonia, primary, Bighin, Claudia, primary, Poggio, Francesca, primary, Lambertini, Matteo, primary, and Del Mastro, Lucia, primary

Published
2023
Full Text
View/download PDF

41. Data from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials

Author

Conte, Benedetta, primary, Boni, Luca, primary, Bisagni, Giancarlo, primary, Durando, Antonio, primary, Sanna, Giovanni, primary, Gori, Stefania, primary, Garrone, Ornella, primary, Tamberi, Stefano, primary, De Placido, Sabino, primary, Schettini, Francesco, primary, Pazzola, Antonio, primary, Ponzone, Riccardo, primary, Montemurro, Filippo, primary, Lunardi, Gianluigi, primary, Notaro, Rosario, primary, De Angioletti, Maria, primary, Turletti, Anna, primary, Mansutti, Mauro, primary, Puglisi, Fabio, primary, Frassoldati, Antonio, primary, Porpiglia, Mauro, primary, Fabi, Alessandra, primary, Generali, Daniele, primary, Scognamiglio, Giovanni, primary, Rossi, Maura, primary, Brasó-Maristany, Fara, primary, Prat, Aleix, primary, Cardinali, Barbara, primary, Piccioli, Patrizia, primary, Serra, Martina, primary, Lastraioli, Sonia, primary, Bighin, Claudia, primary, Poggio, Francesca, primary, Lambertini, Matteo, primary, and Del Mastro, Lucia, primary

Published
2023
Full Text
View/download PDF

42. Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial

Author

Conte, PierFranco, primary, Bisagni, Giancarlo, additional, Piacentini, Federico, additional, Sarti, Samanta, additional, Minichillo, Santino, additional, Anselmi, Elisa, additional, Aieta, Michele, additional, Gebbia, Vittorio, additional, Schirone, Alessio, additional, Musolino, Antonino, additional, Garrone, Ornella, additional, Beano, Alessandra, additional, Rimanti, Anita, additional, Giotta, Francesco, additional, Turletti, Anna, additional, Miglietta, Federica, additional, Dieci, Maria Vittoria, additional, Vicini, Roberto, additional, Balduzzi, Sara, additional, D'Amico, Robert, additional, and Guarneri, Valentina, additional

Published
2023
Full Text
View/download PDF

48. M\'{e}canismes de Transmission Multipoint pour R\'{e}seaux Locaux Sans Fil IEEE 802.11

Author

Turletti, Thierry and Seok, Yongho

Subjects
Computer Science - Networking and Internet Architecture
Abstract

Le standard IEEE 802.11 est inefficace pour la transmission multim\'{e}dia en multipoint. En particulier, les paquets multipoints sont envoy\'{e}s en boucle ouverte de la m\^{e}me mani\`{e}re que les paquets broadcast. L'absence d'acquittements rend impossible la mise en oeuvre de m\'{e}canismes de contr\^{o}le de congestion, de m\'{e}canisme de fiabilisation de la transmission ainsi que d'algorithmes d'adaptation du d\'{e}bit de transmission physique. Dans ce rapport, nous proposons de nouveaux m\'{e}canismes de ransmission multipoint qui se basent sur une approche leader pour renvoyer des acquittements. Nous nous interessons \`{a} des solutions pratiques qui sont suceptibles d'\^{e}tre implant\'{e}s dans les cartes r\'{e}seaux sans fil actuelles et futures et qui restent compatibles avec les stations IEEE 802.11 standards. Nous proposons deux m\'{e}canismes pour adapter le d\'{e}bit de transmission physique des flots multipoints: un m\'{e}canisme simplifi\'{e} appel\'{e} LB-ARF et un m\'{e}canisme plus robuste appel\'{e} RRAM. Nos simulations montrent que pour des environnements statiques, un m\'{e}canisme aussi simple que LB-ARF suffit pour obtenir de bonnes performances. Le m\'{e}canisme RRAM est quant \`{a} lui aussi efficace dans des environnements statiques que lorsque les stations sont mobiles.

Published
2006

49. A Locating-First Approach for Scalable Overlay Multicast

Author

Kaafar, Mohamed Ali Dali, Turletti, Thierry, and Dabbous, Walid

Subjects
Computer Science - Networking and Internet Architecture
Abstract

Recent proposals in multicast overlay construction have demonstrated the importance of exploiting underlying network topology. However, these topology-aware proposals often rely on incremental and periodic refinements to improve the system performance. These approaches are therefore neither scalable, as they induce high communication cost due to refinement overhead, nor efficient because long convergence time is necessary to obtain a stabilized structure. In this paper, we propose a highly scalable locating algorithm that gradually directs newcomers to their a set of their closest nodes without inducing high overhead. On the basis of this locating process, we build a robust and scalable topology-aware clustered hierarchical overlay scheme, called LCC. We conducted both simulations and PlanetLab experiments to evaluate the performance of LCC. Results show that the locating process entails modest resources in terms of time and bandwidth. Moreover, LCC demonstrates promising performance to support large scale multicast applications.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results